NEW YORK, Oct. 11, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Endo International plc (NASDAQ:ENDP) who purchased shares between November 30, 2012 and July 6, 2017. The action, which was filed in the USDC for the Eastern District of Pennsylvania, alleges that the Company violated federal securities laws.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.
Shareholders have until October 17, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/endo-international-plc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com


Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 



